You are here » Home » Companies » Company Overview » Ajanta Pharma Ltd

Ajanta Pharma Ltd.

BSE: 532331 Sector: Health care
NSE: AJANTPHARM ISIN Code: INE031B01049
BSE LIVE 15:40 | 24 Mar 1827.35 -8.95
(-0.49%)
OPEN

1838.35

HIGH

1850.00

LOW

1822.40

NSE LIVE 15:49 | 24 Mar 1834.75 -5.45
(-0.30%)
OPEN

1840.20

HIGH

1852.70

LOW

1827.00

OPEN 1838.35
PREVIOUS CLOSE 1836.30
VOLUME 7124
52-Week high 2150.00
52-Week low 1311.75
P/E 30.42
Mkt Cap.(Rs cr) 16080.68
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00
OPEN 1838.35
CLOSE 1836.30
VOLUME 7124
52-Week high 2150.00
52-Week low 1311.75
P/E 30.42
Mkt Cap.(Rs cr) 16080.68
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00

Ajanta Pharma Ltd. (AJANTPHARM) - Company History

Ajanta Pharma is a specialty pharmaceutical company engaged in development manufacture and marketing of quality finished dosages in domestic and international markets. Committed to Serve Health Care Needs Worldwide. The company produces a comprehensive range of specialty products targeting different therapeutic segments for treatment of patients customised to each market the company is present in. The company clearly understands customer's needs and uses cutting edge technology to present innovative solutions. The company's business includes Branded Generics in emerging markets of Asia and Africa Generics in the developed markets of USA and Institution sales.Established in 1973 and headquartered in Mumbai-India the company has a mission of Serving Global Health Care Needs Worldwide. Ajanta has been consistently providing affordable and quality medicines to patients in different parts of the world. The company began its operation in the year 1973 by setting up a small repackaging unit. The company also launched 4 products under its own brand name for repackaged pharma items in the same year. In 1979 the Company set up its 1stManufacturing factory in Chikalthana Maharashtra and also launched 1st own manufactured OTC product- Pinkoo Gripe Water making a mark in the industry by deviating from easy path of following leaders in gripe water industry. A New Manufacturing Facility was built by the company in the year 1984 in Paithan and the company also entered in institutional business. During the period between 1995 to 1998 the company established dedicated R&D facility at Kandivli and also set up manufacturing facilities in Mauritius and CIS. In 2000 the company went public with shares by listing shares in BSE and NSE and also undertook major expansion of manufacturing facilities. In 2002 the company entered domestic prescription market with speciality segment force. In 2007 the company expanded its R&D facility with independent premises in Kandivali. The company also got USFDA Approval for its paithan manufacturing facility in 2008. In 2009 the company started Active Pharmaceutical Ingredient (API) plant in Waluj Aurangabad for captive use.Today the branded generics business is spread in India and more than 30 emerging countries across Africa CIS the Middle East and South East Asia. In India the company has presence in high growth specialty segments of cardiology dermatology ophthalmology and pain management where the company has been able to provide consistently innovative products many being 1st to the market for patient convenience and compliance. Emerging markets are the major contributors in the companies branded generic business where the company is present across Asia and Africa. The company has designed customised basket of products for each of these markets and serve wide range of therapeutic segments like Anti-Biotic Anti-Malarial Anti-Diabetic Cardiology Gynecology Orthopedics Pediatric Respiratory & General Health products.The company has recently entered the regulated markets of USA with select product portfolio which include complex technology products to get the competitive advantage in the market place. The company expects US market to be a key growth driver in the coming years. The Company's Institutional business comprises of supplies to various government bodies in India and supply of Anti-Malarial products under WHO approved programs in Africa.Ajanta operates with 6 state-of-the art manufacturing facilities that produce high quality pharmaceutical products. Currently one of the facility is already approved by US FDA and another facility is getting ready for the same. The company is further expanding its manufacturing capabilities to meet growth requirement in future.The company has an advanced Research & Development Centre for finished formulations and Active Pharmaceutical Ingredient (API) synthesis of different dosage forms. The companies R&D centre has a team of scientists working on innovative products for various markets across the globe. The company has acquired strong capabilities for developing generic formulations and process chemistry over the years. The company also employs over 6000 people worldwide with products are sold in over 30 countries.In 2015 the company announces the Launch of Montelukast Sodium Oral Granules. The company also announched the Launch of Montelukast lR Tablets and Montelukast Chewable Tablets in US market.Till Date the company has launched 12 products in the US Market.